Senate Report Says Medtronic Inc. Manipulated Infuse Bone Graft Product Review Data

Tweet

October 25, 2012 – The U.S. Senate Committee on Finance published a report today accusing medical device manufacturer Medtronic Inc. of editing health journal articles and giving kickbacks to physicians who conducted company-sponsored studies of its Infuse Bone Graft product. According to the report, Medtronic’s role in editing the articles was not disclosed by the company, and that by law, “Medical journals should ensure industry role contributions be fully disclosed.” The senate inquiry began in June last year, after rumors flew about surgeons being paid by Medtronic to omit complications associated with the Infuse.

Medtronic Infuse Bone Graft Lawsuit Update 12/10/12: A medical malpractice lawsuit has been filed on behalf of a Pennsylvania man who allegedly experienced severe side effects after undergoing a spinal fusion procedure where the Medtronic Infuse BMP was used as an alternative to a traditional bone graft. The complaint alleges that the design of the Medtronic Infuse, as well as a lack of proper medical care by the surgeon, caused the plaintiff to suffer permanent injuries following the surgery. Click here to learn more.

Free Medtronic Infuse Lawsuit Evaluation: If you or a loved one has been injured by a Medtronic Infuse Bone Graft product, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against Medtronic Inc. and we can help.

What’s the problem?

In addition to secretly editing numerous health journal articles, the Senate Committee on Finance is accusing Medtronic of deceptively marketing Infuse, a synthetic protien used in spinal surgery, as a superior technique to bone grafts from the pelvis, and of paying out approximately $210 million in royalties and ‘consulting fees’ to doctors who conducted company sponsored studies over a period of nearly 15 years.

In an issue of the Spine Journal that was published a week after the senate inquiry, it was reported that 13 studies of Infuse that were sponsored by Medtronic found absolutely no adverse events associated with the product. The Committee report was published after members reviewed over 5,000 documents related to the Infuse safety trials.

First approved by the U.S. Food & Drug Administration (FDA) for spinal surgery in 2002, the Medtronic Infuse Bone Graft generated sales of approximately $800 million in the fiscal year 2011.

Do I Have a Medtronic Infuse Lawsuit?

The Medical Device Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Medtronic Infuse Bone Graft product lawsuits. We are handling individual litigation nationwide and currently accepting new injury cases in all 50 states.

Free Medtronic Infuse Bone Graft Lawsuit Evaluation: If you or a loved one has been injured by a Medtronic Infuse Bone Graft Product, you should contact our law firm immediately. You may be entitled to compensation by filing a Medtronic Infuse suit and we can help.